Eric Sprott announces holdings in Entheon Biomedical Corp.

 

Eric Sprott beneficially owns and controls 3.2 million common shares and 1.1 million share purchase warrants of Entheon Biomedical Corp., representing approximately 7.9 per cent on a non-diluted basis of the outstanding shares and 10.4 per cent on a partially diluted basis, assuming the exercise of such warrants.

Mr. Sprott understands that Entheon Biomedical has commenced trading on the Canadian Securities Exchange, effective Nov. 12, 2020, under the symbol ENBI, following a business combination with Entheon Holdings Corp. (formerly Entheon Biomedical Corp.).

The securities owned by Mr. Sprott through the business combination are held for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities of Entheon Biomedical, including on the open market or through private acquisitions, or sell securities of Entheon Biomedical, including on the open market or through private dispositions, in the future depending on market conditions, reformulation of plans and/or other relevant factors.

A copy of the early warning report with respect to the foregoing will appear on the company's profile on SEDAR and may also be obtained by calling Mr. Sprott's office at 416-945-3294 (200 Bay St., Suite 2600, Royal Bank Plaza, South Tower, Toronto, Ont., M5J 2J1).

 

 

To contact us please email rick@aheadoftheherd.com

Ahead of the Herd
www.aheadoftheherd.com